Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELISPOT-guided immunosuppression minimization after de novo kidney transplantation
NL-OMON45147Phase 2Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tacrolimus, basiliximab, mycophenolate mofetil and corticosteroids in kidney transplant (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Biopsy-proven acute rejection at 6 months. Started Jan 2016; status: recruiting.
02
Drugs
tacrolimusbasiliximabmycophenolate mofetilcorticosteroids
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON45147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45147.